Return to homepagePandemic Pact

Favipiravir, lopinavir/ritonavir or combination therapy: a randomised, double blind, 2×2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 (the FLARE trial)

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    LifeArc

  • Principal Investigator

    Unspecified Unspecified Unspecified

  • Research Location

    United Kingdom

  • Lead Research Institution

    University College London

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Phase 2 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Health Personnel

Abstract

University College London (UCL), with funding from LifeArc, is set to conduct a placebo-controlled clinical trial to determine if early treatment with antiviral drugs favipiravir and lopinavir/ritonavir prevents the progression of COVID-19 in healthcare workers who have experienced symptoms for less than 3 days. Favipiravir, as a single therapeutic, has demonstrated early signs that is might offer potential clinical benefit in COVID-19 and both drugs have the potential to inhibit replication of SARS-CoV-2. This UCL study aims to investigate the effect of favipiravir, lopinavir/ritonavir or the combination of both drugs on reducing viral load.